RSS Feeds
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
- Catherine MacLean, MD, PhD;
- Sydne Newberry, PhD;
- Margaret Maglione, MPP;
- Maureen McMahon, MD;
- Veena Ranganath, MD;
- Marika Suttorp, MS;
- Walter Mojica, MD;
- Martha Timmer, MS;
- Alicia Alexander, MD;
- Melissa McNamara, MD;
- Sheetal B. Desai, MD, MS;
- Annie Zhou, MS;
- Susan Chen, BA;
- Jason Carter, BA;
- Carlo Tringale, BA;
- Di Valentine, JD;
- Breanne Johnsen, BA; and
- Jennifer Grossman, MD
- From the Southern California Evidence-based Practice Center, which includes RAND, Santa Monica, and the Greater Los Angeles Veterans Administration Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.
-
Figure 1. Study flow diagram.PTH = parathyroid hormone; SERM = selective estrogen receptor modulator. *Articles are not mutually exclusive.
-
Figure 2. Risk for vertebral fractures relative to placebo for participants who are at high risk for fracture, by agent.PTH = parathyroid hormone; SERM = selective estrogen receptor modulator. *Pooled risk estimate from cited meta-analysis or systematic review. †Pooled risk estimate calculated by authors; restricted to studies with >12 months of follow-up. ‡Risk estimate calculated from cited individual studies. §Insufficient data to calculate risk.
-
Figure 3. Risk for nonvertebral fractures relative to placebo for participants who are at high risk for fracture, by agent.NR = not reported; PTH = parathyroid hormone; SERM = selective estrogen receptor modulator. *Pooled risk estimate from cited meta-analysis or systematic review. †Pooled risk estimate calculated by authors; restricted to studies with >12 months of follow-up. ‡Risk estimate calculated from cited individual studies. §Insufficient data to calculate risk.
-
Figure 4. Risk for hip fractures relative to placebo for participants who are at high risk for fracture, by agent.NR = not reported; PTH = parathyroid hormone; SERM = selective estrogen receptor modulator. *Pooled risk estimate from cited meta-analysis or systematic review. †Insufficient data to calculate risk. ‡Risk estimate calculated from cited individual studies.
-
Appendix Figure 1. Risk for vertebral fracture relative to placebo for participants who are not at high risk for fracture, by agent.NR = not reported; PTH = parathyroid hormone; SERM = selective estrogen receptor modulator; WHI = Women's Health Initiative. *Pooled risk estimate from cited meta-analysis or systematic review. †Insufficient data to calculate risk. ‡Risk estimate calculated from cited individual studies.
-
Appendix Figure 2. Risk for nonvertebral fracture relative to placebo for participants who are not at high risk for fracture, by agent.NR = not reported; PTH = parathyroid hormone; SERM = selective estrogen receptor modulator. *Pooled risk estimate from cited meta-analysis or systematic review. †Insufficient data to calculate risk. ‡Risk estimate calculated from cited individual studies.
-
Appendix Figure 3. Risk for hip fracture relative to placebo for participants who are not at high risk for fracture, by agent.NR = not reported; PTH = parathyroid hormone; SERM = selective estrogen receptor modulator; WHI = Women's Health Initiative. *Pooled risk estimate from cited meta-analysis or systematic review. †Insufficient data to calculate risk. ‡Risk estimate calculated from cited individual studies.
Related Clinical Content
